Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis
Trieu-My Van, … , Nikoletta Papadopoulou, Manolis Pasparakis
Trieu-My Van, … , Nikoletta Papadopoulou, Manolis Pasparakis
Published June 19, 2017
Citation Information: J Clin Invest. 2017;127(7):2662-2677. https://doi.org/10.1172/JCI92508.
View: Text | PDF
Research Article Hepatology Inflammation

Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis

  • Text
  • PDF
Abstract

The mechanisms that regulate cell death and inflammation play an important role in liver disease and cancer. Receptor-interacting protein kinase 1 (RIPK1) induces apoptosis and necroptosis via kinase-dependent mechanisms and exhibits kinase-independent prosurvival and proinflammatory functions. Here, we have used genetic mouse models to study the role of RIPK1 in liver homeostasis, injury, and cancer. While ablating either RIPK1 or RelA in liver parenchymal cells (LPCs) did not cause spontaneous liver pathology, mice with combined deficiency of RIPK1 and RelA in LPCs showed increased hepatocyte apoptosis and developed spontaneous chronic liver disease and cancer that were independent of TNF receptor 1 (TNFR1) signaling. In contrast, mice with LPC-specific knockout of Ripk1 showed reduced diethylnitrosamine-induced (DEN-induced) liver tumorigenesis that correlated with increased DEN-induced hepatocyte apoptosis. Lack of RIPK1 kinase activity did not inhibit DEN-induced liver tumor formation, showing that kinase-independent functions of RIPK1 promote DEN-induced hepatocarcinogenesis. Moreover, mice lacking both RIPK1 and TNFR1 in LPCs displayed normal tumor formation in response to DEN, demonstrating that RIPK1 deficiency decreases DEN-induced liver tumor formation in a TNFR1-dependent manner. Therefore, these findings indicate that RIPK1 cooperates with NF-κB signaling to prevent TNFR1-independent hepatocyte apoptosis and the development of chronic liver disease and cancer, but acts downstream of TNFR1 signaling to promote DEN-induced liver tumorigenesis.

Authors

Trieu-My Van, Apostolos Polykratis, Beate Katharina Straub, Vangelis Kondylis, Nikoletta Papadopoulou, Manolis Pasparakis

×

Figure 7

LPC-specific deficiency of RIPK1 attenuates obesity-induced liver carcinogenesis.

Options: View larger image (or click on image) Download as PowerPoint
LPC-specific deficiency of RIPK1 attenuates obesity-induced liver carcin...
(A) BW curve of NCD- or HFD-fed DEN-injected Ripk1fl/fl and RIPK1LPC-KO mice starting from DEN injection until the age of 36 weeks. Mean ± SEM. (B and C) Graph depicting serum ALT level (B) and serum LDL cholesterol level (LDL-C) (C) of NCD- or HFD-fed 36-week-old Ripk1fl/fl and RIPK1LPC-KO mice upon DEN injection. (D) Graphs depicting blood glucose levels after glucose administration in NCD- or HFD-fed Ripk1fl/fl and RIPK1LPC-KO mice at 12 and 24 weeks of age. Mean ± SEM. (E) Representative photographs of livers and H&E-stained liver sections from DEN-injected Ripk1fl/fl and RIPK1LPC-KO mice at the age of 36 weeks. Scale bars: 1 cm (left panels); 100 μm; (right panels). HCC/dysplastic nodule areas are marked with an asterisk. (F) Tumor load in NCD- or HFD-fed 36-week-old Ripk1fl/fl and RIPK1LPC-KO mice as estimated by quantification of the tumor size distribution. ***P < 0.005, χ2 test. (G) Graphs depicting the number of tumors per liver in 36-week-old mice injected with DEN. *P < 0.05, 1-way ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts